Evidence map›Paper›PMID 24348039›Full record

ArticleInternational journal of nanomedicine2013

Evaluating the potential of poly(beta-amino ester) nanoparticles for reprogramming human fibroblasts to become induced pluripotent stem cells.

Nupura S Bhise, Karl J Wahlin, Donald J Zack, Jordan J Green

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Dynamic changes in mRNA isoform usage during human retinal development.bioRxiv : the preprint server for biology · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. In situ genetic engineering of tumors for long-lasting and systemic immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Nupura S BhiseDepartment of Biomedical Engineering, Translational Tissue Engineering Center, and Institute for Nanobiotechnology, Baltimore, MD, USA.
Karl J WahlinDepartment of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Donald J ZackDepartment of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA ; Solomon H Snyder Department of Neuroscience, Department of Molecular Biology and Genetics, and Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA ; Institut de la Vision, Paris, France.
Jordan J GreenDepartment of Biomedical Engineering, Translational Tissue Engineering Center, and Institute for Nanobiotechnology, Baltimore, MD, USA ; Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins University · USInstitut de la Vision · FR

Funding

Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI Jiang Qian · 1985 to 2026
$22.1M
REGULATION OF RHODOPSIN GENE EXPRESSIONR01EY009769 · NEI · JOHNS HOPKINS UNIVERSITY · PI ZACK, DONALD J. · 1992 to 2014
$8.1M
Gene Delivery Nanoparticles to Treat GlioblastomaR01EB016721 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI GREEN, JORDAN · 2013 to 2017
$1.9M
NEI NIH HHS P30 EY001765NEI NIH HHS P30EY001765NEI NIH HHS R01 EY009769NEI NIH HHS R01EY009769NIBIB NIH HHS 1R01EB016721NIBIB NIH HHS R01 EB016721
6 · The paper itself

Abstract

backgroundGene delivery can potentially be used as a therapeutic for treating genetic diseases, including neurodegenerative diseases, as well as an enabling technology for regenerative medicine. A central challenge in many gene delivery applications is having a safe and effective delivery method. We evaluated the use of a biodegradable poly(beta-amino ester) nanoparticle-based nonviral protocol and compared this with an electroporation-based approach to deliver episomal plasmids encoding reprogramming factors for generation of human induced pluripotent stem cells (hiPSCs) from human fibroblasts.

methodsA polymer library was screened to identify the polymers most promising for gene delivery to human fibroblasts. Feeder-independent culturing protocols were developed for nanoparticle-based and electroporation-based reprogramming. The cells reprogrammed by both polymeric nanoparticle-based and electroporation-based nonviral methods were characterized by analysis of pluripotency markers and karyotypic stability. The hiPSC-like cells were further differentiated toward the neural lineage to test their potential for neurodegenerative retinal disease modeling.

results1-(3-aminopropyl)-4-methylpiperazine end-terminated poly(1,4-butanediol diacry-late-co-4-amino-1-butanol) polymer (B4S4E7) self-assembled with plasmid DNA to form nanoparticles that were more effective than leading commercially available reagents, including Lipofectamine® 2000, FuGENE® HD, and 25 kDa branched polyethylenimine, for nonviral gene transfer. B4S4E7 nanoparticles showed effective gene delivery to IMR-90 human primary fibroblasts and to dermal fibroblasts derived from a patient with retinitis pigmentosa, and enabled coexpression of exogenously delivered genes, as is needed for reprogramming. The karyotypically normal hiPSC-like cells generated by conventional electroporation, but not by poly(beta-amino ester) reprogramming, could be differentiated toward the neuronal lineage, specifically pseudostratified optic cups.

conclusionThis study shows that certain nonviral reprogramming methods may not necessarily be safer than viral approaches and that maximizing exogenous gene expression of reprogramming factors is not sufficient to ensure successful reprogramming.

Indexed as

Cellular ReprogrammingCell DifferentiationCell LineElectroporationFibroblastsHumansInduced Pluripotent Stem CellsKaryotypeMicroscopy, FluorescenceNanoparticlesPolymersTransfectionpoly(beta-amino ester)Polymershuman fibroblastsinduced pluripotent stem cellspoly(beta-amino ester) nanoparticlesreprogramming

Identifiers

PMID24348039
PMCPMC3857166
OpenAlexW2031863655

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.